A Phase 1 Single-dose Open Label 3-way Crossover Study To Evaluate The Bioavailability Of A Spray Dried Dispersion Solid Dose Formulation Of Pf-06260414 Relative To A Suspension Formulation Under Fasted Conditions And The Effect Of Food On The Bioavailability Of The Pf-06260414 Spray Dried Dispersion Solid Formulation In Healthy Subjects

Trial Profile

A Phase 1 Single-dose Open Label 3-way Crossover Study To Evaluate The Bioavailability Of A Spray Dried Dispersion Solid Dose Formulation Of Pf-06260414 Relative To A Suspension Formulation Under Fasted Conditions And The Effect Of Food On The Bioavailability Of The Pf-06260414 Spray Dried Dispersion Solid Formulation In Healthy Subjects

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 01 May 2015

At a glance

  • Drugs PF 626414 (Primary)
  • Indications Cachexia
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Apr 2015 Planned End Date changed from 1 May 2015 to 1 Jul 2015 as per ClinicalTrials.gov record.
    • 27 Apr 2015 Planned primary completion date changed from 1 May 2015 to 1 Jul 2015 as per ClinicalTrials.gov record.
    • 27 Apr 2015 Planned initiation date changed from 1 Apr 2015 to 1 Jun 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top